替格瑞洛讲座PPT参考幻灯片.pptVIP

* * PEGASUS-TIMI 54 * PEGASUS-TIMI 54 PATIENTS 21162? patients with a history of spontaneous myocardial infarction within 1 to 3 years TIME ?October 2010 ～ April 2013? DESINE a randomized, double-blind, placebo-controlled, multinational clinical trial? PURPOSE evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events Primary endpoint cardiovascular death, myocardial infarction, or stroke Program ASA+ ticagrelor 90 mg twice daily vs. ASA+?ticagrelor 60 mg twice daily vs. ASA+ matching placebo ?Followed-UP At least 12 months * Result:Ticagrelor 90mg,60mg vs placebo ?Reduced the rate of the primary end point 15%, 16% Bonaca MP. N?Engl?J?Med.?2015?May 7;372(19):1791-800. * * Efficacy End Points as 3 year Kaplan-Meier Estimates(%) * TIMI 主要出血 TIMI 轻微出血 致死性出血 或颅内出血 颅内出血 致死性出血 P0.001 P0.001 P=NS P=NS P=NS * ESC/EACTS：欧洲心脏病协会/欧洲心胸外科协会(European Society of Cardiology/The European Association of Cardio-Thoracic Surgery)。 * ACCF:美国心脏病学会基金会(American College of Cardiology Foundation).ACCP:美国胸科医师协会（American College of Chest Physicians） * CCS：加拿大心血管学会（Canadian Cardiovascular Society）。 * 替格瑞洛（倍林达）在抗血小板聚集中的作用 Ticagrelor for the role of anti-platelet aggregation 昌平区中医医院：张碎虎 * content 概述 临床效应 替格瑞洛作用机制 推荐使用替格瑞洛（倍林达）指南 Ticagrelor Changping chineses medicine hospital * 噻吩吡啶类药物发展史 Anti-platelet aggregation 噻氯匹定 法国 Sanofi-aventis 1979年 氯吡格雷 美国 Sanofi-aventis 1998年 普拉格雷 日本，美国 Daiichi Sankyo Eli Lilly 2009年 普格瑞洛 瑞典 AstraZeneca AB 2010年 卜晓斐.现代药物与临床,27(1). * 血小板血栓形成过程 Adhesion 1 * Activation 2 Thrombin ADP 5 HT P